ArticleFrontiers in microbiology2026
Synergistic inhibition of
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Materials and methods: Synergistic interactions between NaF and EGCG were first assessed by crystal violet staining and checkerboard microdilution analysis. Biofilm biomass, viability, and matrix composition were quantified using colony-forming unit assays, scanning electron microscopy, confocal laser scanning microscopy, and measurements of water-insoluble extracellular polysaccharides. Transcriptomic, proteomic, and metabolomic profiling were carried out to identify perturbed pathways, and arginine levels were quantified to evaluate metabolic responses. Results: Co-treatment with NaF and EGCG produced a synergistic inhibitory effect, markedly reducing biomass, viable cells, and extracellular polysaccharide content. Microscopic analyses demonstrated disrupted microcolony organization and compromised matrix architecture. Multi-omics profiling revealed concentration-dependent alterations in amino acid, carbohydrate metabolism, nucleotide and energy-related processes. Conclusion: NaF and EGCG synergistically disrupt
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.